HER2-NEGATIVE BREAST CANCER

This study tests an experimental vaccine made from a patient's own immune cells (dendritic cells) that are trained to recognize HER2 and HER3 proteins. The vaccine is injected directly into the tumor along with standard chemotherapy before surgery. The goal is to see if this comb…

This study is for people with a type of breast cancer called HER2-negative that has spread to the brain. It tests whether adding a drug called anlotinib to standard radiation therapy can help control the cancer in the brain for longer. About 39 participants will receive this comb…

This study tests a new drug called PC14586 (rezatapopt) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The goal is to see if the drug is safe and shrinks tumors. About 300 adults whose cancer has worsened after prior treatment will take the drug al…

This phase 3 study tests whether adding capivasertib to standard hormone therapy helps people with HR+/HER2- advanced breast cancer stay on treatment longer and maintain quality of life. About 250 adults whose cancer worsened after prior hormone therapy will take capivasertib plu…

This study tests whether adding retinoic acid (a vitamin A derivative) to an immune checkpoint inhibitor can help shrink or control tumors in people with HER2-negative breast cancer whose disease got worse on prior immunotherapy. About 10 participants will receive the combination…

This study is testing a treatment for early-stage breast cancer that combines breast-conserving surgery with a single dose of radiation given during the operation. It involves 620 women aged 55 or older with small, HER2-negative tumors. The goal is to see if this approach lowers …

This early-phase study tests a new drug called BGB-43395, which blocks a protein (CDK4) that helps cancer cells grow. It is for people with advanced hormone receptor-positive, HER2-negative breast cancer or other solid tumors that have spread. The study aims to find the safest an…

This study tests whether combining two drugs—elacestrant and trastuzumab deruxtecan—can shrink tumors in people with a certain type of advanced breast cancer (HR+, HER2-low or ultra-low) that has stopped responding to standard hormone therapy and CDK4/6 inhibitors. About 65 parti…

This study tests whether a daily pill (Z-endoxifen) plus a monthly shot (goserelin) can slow or stop tumor growth in premenopausal women with ER+/HER2- breast cancer. About 87 participants will take the combination for up to 24 weeks before surgery. The main goal is to see if the…

This early-stage study tests a new drug, RLY-2608, designed to target a specific genetic mutation (PIK3CA) found in some advanced solid tumors and breast cancers. The trial will enroll about 930 adults whose cancer has not responded to other treatments. Researchers aim to find th…

This study tests a drug called sacituzumab govitecan, given before surgery, in people with localized triple-negative breast cancer. The goal is to see if it can eliminate all signs of cancer in the breast and lymph nodes at the time of surgery. About 260 participants will receive…

This study tests whether a device called TheraBionic P1, which delivers targeted radio waves, can help shrink early-stage breast cancer before surgery. About 24 women with hormone receptor-positive, HER2-negative breast cancer will use the device daily for a short time before the…

This study is for people with a type of breast cancer (hormone receptor-positive, HER2-negative) that has come back in the same area after initial treatment. The goal is to see if adding the drug ribociclib to standard hormone therapy can help prevent the cancer from returning ag…

This study looks at whether giving chemotherapy directly into the fluid around the brain (via a small device called an Ommaya reservoir) along with standard body-wide chemo works better than standard chemo alone for people with HER2-negative breast cancer that has spread to the b…

This study tests whether adding everolimus to elacestrant can help people with a certain type of advanced breast cancer (ER+/HER2-, with an ESR1 mutation) live longer without their cancer growing. About 240 adults whose cancer has worsened after standard treatments will receive e…

This study is testing whether tirzepatide, a drug used for weight loss, can help people with early-stage hormone-positive breast cancer lose at least 5% of their body weight during their regular cancer treatment. About 40 participants will take the drug and be monitored for safet…

This early-stage study tests a new drug called BGB-21447, which blocks a protein that helps cancer cells survive. It is given together with standard hormone therapy (fulvestrant) and sometimes another targeted drug (BGB-43395) to adults with HR+/HER2- breast cancer that has sprea…

This study tests whether a new drug, RLY-2608, combined with fulvestrant works better than another drug combo (capivasertib + fulvestrant) for people with a specific genetic mutation (PIK3CA) in advanced hormone-receptor-positive, HER2-negative breast cancer. About 540 adults who…

This study is for women with a certain type of breast cancer (ER+HER2-) who have already had radiation once and now need a second lumpectomy. Researchers want to see if giving radiation again is safe and helps prevent the cancer from coming back. About 114 participants will be fo…

This early-phase study is testing an experimental drug called DR-0202 in people with advanced solid tumors (like breast, lung, or pancreatic cancer) that have stopped responding to standard treatments. The main goal is to check the drug's safety and find the right dose. About 96 …

This study tests a three-drug combination (alpelisib, L-NMMA, and chemotherapy) in people with a rare, aggressive type of breast cancer called metaplastic breast cancer that has spread or is locally advanced and hasn't responded to prior treatments. The goal is to see if adding t…

This early-stage trial is testing a new treatment for people with metastatic pancreatic or breast cancer that has spread. The treatment combines chemotherapy drugs with high-dose vitamin C and the patient's own stem cells to try to overcome drug resistance. The main goal is to ch…

This study tests a drug called elacestrant against standard hormone therapy in 220 people with ER+/HER2- breast cancer who show signs of cancer DNA in their blood (ctDNA) but no distant spread. The goal is to see if elacestrant can delay or prevent the cancer from returning elsew…

This study tests different doses of the drug abemaciclib given together with radiation therapy for people with advanced hormone receptor-positive, HER2-negative breast cancer that has spread to the bone. The goal is to find the safest dose of abemaciclib when used alongside stand…

This early-phase study tests an experimental oral drug, RGT-490, in adults with advanced solid tumors (including breast, ovarian, and endometrial cancers) that have a specific genetic change called PIK3CA. The main goals are to check safety, find the right dose, and see if the dr…

This study looks at whether giving hormone therapy before surgery can lower the chance of cancer cells being found at the edges of removed tissue in women with stage 2 to 3 invasive lobular breast cancer. About 176 postmenopausal women with ER+/HER2- tumors will receive neoadjuva…

This study tests a combination of three drugs (anastrozole, fulvestrant, and abemaciclib) in 20 people with a common type of advanced breast cancer (HR-positive, HER2-negative). The goal is to see how well the treatment shrinks or controls the cancer. Participants either have new…

This study tests a new drug called OP-1250 (Palazestrant) combined with other targeted therapies in people with advanced or metastatic ER-positive, HER2-negative breast cancer. About 190 adults will receive one of four drug combinations to find the safest dose and understand side…

This study is for people with a certain type of advanced breast cancer (ER-positive, HER2-negative) that has stopped responding to a common first treatment. The trial will test a combination of two drugs, fulvestrant and abemaciclib, after a short break from the previous treatmen…

This early study tests whether combining a dendritic cell vaccine (DC1) with the drug elacestrant is safe and doable for people with hormone-positive, HER2-negative breast cancer that has spread. About 18 participants will receive the treatment for 8 weeks. The goal is to see if …

This study is for premenopausal women with a common type of breast cancer (HR+/HER2-). It tests a drug called elacestrant, given alone or with another drug (triptorelin), for 4 weeks before surgery. The goal is to see if the treatment lowers a marker of cancer growth (Ki67) in th…

This study tests two antibody drug conjugates (datopotamab deruxtecan and trastuzumab deruxtecan) given one after the other in people with HER2-negative metastatic breast cancer that has worsened after prior treatment. The goal is to see if this sequence can shrink tumors or slow…

This study looks at whether giving antibody-drug conjugates (ADCs) a second time is safe and effective for people with advanced breast cancer that has spread. About 160 adults who have already received ADCs will be enrolled. The goal is to see if the tumors shrink or stop growing…

This study is for women with an early, hormone-sensitive type of breast cancer that has a higher chance of coming back. It tests whether a blood test (ctDNA) can identify who can safely skip chemotherapy and instead take a targeted pill (dalpiciclib) plus hormone therapy. About 3…

This study tests a new imaging system that uses light to monitor how well breast cancer responds to chemotherapy before surgery. Researchers want to see if it can accurately predict when the cancer is completely gone, which could help some patients avoid additional treatments. Th…

This study tests a decision aid for women aged 70 and older with early-stage, low-risk breast cancer. The tool helps them and their doctors discuss treatment options, aiming to reduce aggressive treatments like mastectomy or radiation when they may not be needed. About 400 partic…

This study is tracking 100 people with HER2-negative metastatic breast cancer who are receiving antibody-drug conjugates (ADCs) as part of their normal care. Researchers want to see how long these drugs control the cancer in real-world settings. The goal is to gather information …

This study is testing whether adding new experimental drugs to standard chemotherapy before surgery can improve outcomes for people with breast cancer. It includes up to 5,000 participants with early-stage or locally advanced breast cancer. The goal is to use MRI scans and tissue…

This study is looking at a test called EndoPredict that helps doctors decide if women with a certain type of early breast cancer need chemotherapy or just hormone therapy. The test measures the risk of the cancer coming back over 10 years. The goal is to see if using this test in…

This study is testing a blood test called DiviTum TKa to see if it can predict when hormone-receptor-positive (HR+) metastatic breast cancer stops responding to treatment. About 100 people starting standard therapies (endocrine therapy with or without a CDK4/6 inhibitor) will giv…

This study looks at whether a protein called PSMA, usually found in prostate cancer, is present in a certain type of advanced breast cancer (HER2-negative, AR-positive). Researchers will use a special PET/CT scan to measure PSMA levels in up to 15 participants. The goal is to see…

This study looks at how well women with early-stage, hormone-positive breast cancer take their prescribed medications (aromatase inhibitors with or without abemaciclib). About 319 participants will be followed for 6 months to see if those on the combination therapy have lower adh…